MITOCHONDRIAL DISEASE THERAPY
| Autor: | Vineeta Sawhney, Kanika Khajuria, Vijay Khajuria |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Asian Journal of Pharmaceutical and Clinical Research. :24-30 |
| ISSN: | 2455-3891 0974-2441 |
| DOI: | 10.22159/ajpcr.2021.v14i5.41046 |
| Popis: | Mitochondria perform number of important functions, including synthesis of adenosine triphosphate (ATP) and generation of reactive oxygen species (ROS). Most of the organs depend on ATP to perform. Therefore, in depleted or dysfunctional mitochondrial states, there is less energy production coupled with the accumulation of oxidants. Oxidative stress is involved in the pathophysiology of various disorders especially involving neurons and the cardiovascular system. Mitochondrial diseases are a clinically heterogeneous group of disorders resulting from either inherited or spontaneous mutations in mitochondrial deoxyribonucleic acid (mtDNA) or nuclear DNA. In primary mitochondrial dysfunction disease, the mutation affects the oxidative phosphorylation (OXPHOS) functioning, while secondary mitochondrial dysfunction does not involve OXPHOS genes. Since mutations of genes are involved, therefore, therefore the mitochondrial dysfunctional states are not easy to treat. However, number of strategies that lead to increase ATP production, counter ROS facilitates improvement. The current strategy is to focus on stimulating the biogenesis of mitochondria, antioxidants, and cofactors to enhance ATP synthesis. The role of non-pharmaceuticals cannot be underestimated either. The exercise, diet, and environment influence have well-established beneficial outcome in these disorders. Gene therapy holds promise in the future management of these complex disorders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|